BioRad Laboratories (BIO)
(Delayed Data from NYSE)
$275.94 USD
+0.34 (0.12%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $275.92 -0.02 (-0.01%) 7:58 PM ET
4-Sell of 5 4
D Value D Growth C Momentum D VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
BIO 275.94 +0.34(0.12%)
Will BIO be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for BIO based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for BIO
New Strong Sell Stocks for April 19th
Bio-Rad Laboratories (BIO) to Post Q1 Earnings: What Awaits?
BIO: What are Zacks experts saying now?
Zacks Private Portfolio Services
Bio-Rad (BIO) Hurt by Softness in BioPharma and Competition
Waters (WAT) Boosts Waters Operating Segment With HPLC System
Why Is Perrigo (PRGO) Up 19.1% Since Last Earnings Report?
Other News for BIO
Bio-Rad Announces Life Science Group Management Changes
Bio-Rad Laboratories: Executive Transition and Shareholder Decisions
SPY ETF Update, 4/25/2024���
Danaher gains as Q1 results exceed expectations
Goldman’s debt issuers stocks basket